EUVIMEDEUVIMED entdecken
Crossref

Long-term prognosis of patients surviving progressive multifocal leukoencephalopathy

Nicolas Lambert iD, Majdouline El Moussaoui, Adèle Le Guilloux, Marine Joly iD, Maria Del Carmen Garcia Martearena iD, Ilaria Mainardi, Raphael Bernard-Valnet iD, Carmela Pinnetti, Andrea Antinori iD, Annalisa Mondi, Kirsten Felicity Greve, Xavier Brousse und 45 weitere

Brain · 18.06.2026

DOI: 10.1093/brain/awag213 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain, online erschienen am 18.06.2026. Verfasst von Nicolas Lambert und 56 weiteren Autor:innen. Beteiligte Einrichtung: Experimental Immunotherapeutics Unit, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA. Die Arbeit wurde bisher 2-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite improved survival in recent years, long-term outcomes in patients surviving progressive multifocal leukoencephalopathy beyond the first year remain poorly defined. This international multicenter retrospective study aimed to characterize the three-year prognosis of patients with progressive multifocal leukoencephalopathy who had survived at least one year, identify factors associated with favorable outcomes and late mortality, and determine recurrence rate. Data were collected through standardized questionnaires across forty-one centers in twelve countries. Patients were eligible if they met the 2013 diagnostic criteria for definite progressive multifocal leukoencephalopathy of the American Academy of Neurology, survived at least one year after diagnosis, and had documented follow-up three years after diagnosis. Demographic, clinical, virological, and radiological data were retrieved at diagnosis, one year, and three years. Functional status was assessed using the modified Rankin Scale, with scores of 0-2 defining a favorable outcome. Generalized linear mixed models identified independent predictors of three-year functional status and late mortality. Among 1877 screened cases, 245 patients met inclusion criteria. The most common underlying causes of immunosuppression were HIV infection (48%), autoimmune/inflammatory diseases (26%), and hematological malignancies (18%). At three years, 220 patients (89.8% of the cohort) were alive and 188 (85.5% of survivors) had neurological sequelae, most frequently motor or cognitive impairment. Overall, 112/245 (45.7%) achieved a favorable functional outcome. HIV-associated progressive multifocal leukoencephalopathy (OR 2.36, 95% CI 1.05-5.28) was associated with a favourable outcome, whereas higher modified Rankin Scale score at diagnosis (OR 0.48, 95% CI 0.35-0.66) and higher number of affected brain regions on baseline MRI (OR 0.78, 95% CI 0.64-0.95) were independently associated with poorer functional outcome. Among variables collected one year after diagnosis, good functional status at that time was significantly associated with long-term favorable outcome (OR 0.01, 95% CI <0.01-0.03). Twenty-five patients (10.2%) died after the first year, with mortality associated with higher lesion burden at diagnosis and primary immunodeficiency as underlying disease. Even beyond the first year, progressive multifocal leukoencephalopathy remained the leading cause of death (11/25). Recurrence occurred in seven patients (2.9%) and was almost always fatal (6/7). This study provides a comprehensive evaluation of long-term outcomes among survivors of progressive multifocal leukoencephalopathy. These findings present a nuanced picture: while most remain neurologically impaired, nearly half achieve functional independence at three years. The results emphasize the prognostic relevance of the initial clinical and radiological burden and early functional trajectory and highlight the need for research into mechanisms driving disease recurrence.

Schlagwörter

Stichwörter der Autor:innen

HIVJC virusLong-term outcomePMLPrognosisRelapse

Autor:innen und Institutionen

  • Experimental Immunotherapeutics Unit, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA.
  • Department of Neurology, CHU de Liège/Hôpital de la Citadelle, 4000 Liège, Belgium.
  • ESCMID Study Group for Infectious Diseases of the Brain (ESGIB), 4051 Basel, Switzerland.
  • Department of Clinical Immunology and Internal Medicine, University Hospital of Liège, 4000 Liège, Belgium.
  • Methodology, Data Management and Statistical Analysis Unit, Centre of Clinical Investigation 1436, Department of Medical and Clinical Pharmacology, Toulouse University Hospital, Toulouse University, 31300 Toulouse, Fran…
  • Department of Infectious Diseases, Toulouse University Hospital, Toulouse University, 31300 Toulouse, France.

ORCID-Profile: Nicolas Lambert, Marine Joly, Maria Del Carmen Garcia Martearena, Raphael Bernard-Valnet, Andrea Antinori, Magali Vidal, Alain Makinson, Emmanuel Faure, Martin Martinot, Marin Moutel, Kévin Bouiller, Paul Loubet, Naomi Sayre, Marion Le Marechal, Thomas Skripuletz, Jacob Bodilsen, Paola Cinque

Zitieren

APA

Lambert, N., El Moussaoui, M., Le Guilloux, A., Joly, M., Del Carmen Garcia Martearena, M., Mainardi, I., Bernard-Valnet, R., Pinnetti, C., Antinori, A., Mondi, A., Greve, K. F., Brousse, X., Westendorp, W. F., Wijburg, M. T., Grote-Levi, L., Möhn, N., Pourcher, V., Gressens, S. B., Cruz, C. V., …, & Martin-Blondel, G. (2026). Long-term prognosis of patients surviving progressive multifocal leukoencephalopathy. Brain. https://doi.org/10.1093/brain/awag213

Vancouver

Lambert N, El Moussaoui M, Le Guilloux A, Joly M, Del Carmen Garcia Martearena M, Mainardi I, et al. Long-term prognosis of patients surviving progressive multifocal leukoencephalopathy. Brain. 2026. doi:10.1093/brain/awag213

BibTeX
@article{Lambert2026,
  author = {Lambert, Nicolas and El Moussaoui, Majdouline and Le Guilloux, Adèle and Joly, Marine and Del Carmen Garcia Martearena, Maria and Mainardi, Ilaria and Bernard-Valnet, Raphael and Pinnetti, Carmela and Antinori, Andrea and Mondi, Annalisa and Greve, Kirsten Felicity and Brousse, Xavier and Westendorp, Willeke F and Wijburg, Martijn T and Grote-Levi, Lea and Möhn, Nora and Pourcher, Valérie and Gressens, Simon B and Cruz, Claudina Vicente and van Pesch, Vincent and Vidal, Magali and Redor, Alexis and Makinson, Alain and Konitsioti, Agni M and Hoellinger, Baptiste and Nitsch, Louisa and Ney, Douglas E and Faure, Emmanuel and Alstadhaug, Karl Bjørnar and Martinot, Martin and Genderini, Francesco G and Legras, Joseph and Garzaro, Margaux and Blanchi, Sophie and Gazaignes, Sandrine and Borrelli, Serena and Patrat-Delon, Solène and Vydrář, David and Nicolas-Vullierme, Paul and Moutel, Marin and Cartau, Tom and London, Frédéric and Cabié, André and Bouiller, Kévin and Montcuquet, Alexis and Loubet, Paul and Sayre, Naomi and Le Marechal, Marion and Clifford, David B and Skripuletz, Thomas and Brouwer, Matthijs C and Bodilsen, Jacob and Du Pasquier, Renaud and Cortese, Irene and Cinque, Paola and Sommet, Agnès and Martin-Blondel, Guillaume},
  title = {Long-term prognosis of patients surviving progressive multifocal leukoencephalopathy},
  journal = {Brain},
  year = {2026},
  doi = {10.1093/brain/awag213}
}
Kostenlos starten →